AR114013A1 - ESKETAMINE FOR THE TREATMENT OF DEPRESSION - Google Patents
ESKETAMINE FOR THE TREATMENT OF DEPRESSIONInfo
- Publication number
- AR114013A1 AR114013A1 ARP180103815A ARP180103815A AR114013A1 AR 114013 A1 AR114013 A1 AR 114013A1 AR P180103815 A ARP180103815 A AR P180103815A AR P180103815 A ARP180103815 A AR P180103815A AR 114013 A1 AR114013 A1 AR 114013A1
- Authority
- AR
- Argentina
- Prior art keywords
- esketamine
- depression
- treatment
- clinically proven
- patient
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente proporciona métodos para mantener una remisión estable o respuesta estable lograda por un paciente con depresión después de la administración de una cantidad terapéuticamente eficaz de esketamina durante una fase de administración inicial, que comprende la administración continua de una cantidad terapéuticamente eficaz de esketamina por al menos cinco meses durante una fase de administración posterior. La presente también proporciona métodos para el tratamiento a largo plazo de la depresión en un paciente que comprende administrar al paciente que necesita el tratamiento una cantidad terapéuticamente eficaz clínicamente probada como segura y clínicamente probada como eficaz de esketamina durante al menos seis meses. En algunas modalidades, la depresión es trastorno depresivo mayor o depresión resistente al tratamiento. Reivindicación 15: Un producto farmacéutico que comprende uno o más dispositivos atomizadores intranasales, en donde el uno o más dispositivos comprenden una composición de esketamina y el uno o más dispositivos se configuran para administrar de aproximadamente 28 a aproximadamente 84 mg de esketamina, y en donde el producto farmacéutico está probado clínicamente como seguro y/o probado clínicamente como eficaz para tratar un trastorno depresivo mayor.The present provides methods for maintaining a stable remission or stable response achieved by a patient with depression after administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuous administration of a therapeutically effective amount of esketamine by at least least five months during a subsequent administration phase. The present also provides methods for the long-term treatment of depression in a patient comprising administering to the patient in need of treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some modalities, the depression is major depressive disorder or treatment-resistant depression. Claim 15: A pharmaceutical product comprising one or more intranasal spray devices, wherein the one or more devices comprise an esketamine composition and the one or more devices are configured to deliver from about 28 to about 84 mg of esketamine, and wherein the pharmaceutical product is clinically proven safe and / or clinically proven effective in treating major depressive disorder.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609504P | 2017-12-22 | 2017-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114013A1 true AR114013A1 (en) | 2020-07-08 |
Family
ID=71842928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103815A AR114013A1 (en) | 2017-12-22 | 2018-12-21 | ESKETAMINE FOR THE TREATMENT OF DEPRESSION |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR114013A1 (en) |
-
2018
- 2018-12-21 AR ARP180103815A patent/AR114013A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bettoli et al. | Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. | |
| PH12020500555A1 (en) | Esketamine for the treatment of depression | |
| CL2019003542A1 (en) | Treatment methods for cystic fibrosis. | |
| JP2013155188A5 (en) | ||
| CO2018006358A2 (en) | Treatment of fabry disease in patients not treated and previously treated with ert | |
| EA201791337A1 (en) | COMPOSITIONS OF SUITINIBA AND METHODS OF THEIR APPLICATION IN THE TREATMENT OF EYE DISTURBANCES | |
| PE20142319A1 (en) | MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE | |
| MX2017006938A (en) | Combination therapy for treatment of cancer. | |
| BR112019002461A2 (en) | Dosage regimen for solid tumor treatment | |
| CL2021000030A1 (en) | Use of sgc stimulators for the treatment of mitochondrial disorders | |
| EA202090564A1 (en) | METHODS FOR STRENGTHENING AND / OR STABILIZING THE CARDIAC FUNCTION IN PATIENTS WITH FABRIC DISEASE | |
| PE20181332A1 (en) | METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE | |
| EA202090242A1 (en) | TREATMENT OF FABRY DISEASE IN FZT-NAIVE AND FZT-TREATED PATIENTS | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| NI201000181A (en) | USE OF DRONEDARONE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND WHO HAVE AN INCREASED CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONE. | |
| AR114013A1 (en) | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| BR112015030664A2 (en) | pharmaceutical combination of a pi3k inhibitor and a microtubule destabilizing agent | |
| MX2018011293A (en) | Prolonged release pharmaceutical composition comprising cysteamine or salt thereof. | |
| AR094634A1 (en) | FORMULATION OF 5-AMINOSALYCLIC ACID CAPSULES | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN | |
| BR112018072183A2 (en) | pharmaceutical composition and method for preventing skin disease | |
| BR112018002433A2 (en) | pharmaceutical composition for migraine treatment | |
| EA201590323A1 (en) | METHOD OF INTRODUCTION OF ACTIVE SUBSTANCES IN THE HEAD BRAIN | |
| EA201592261A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING AGOMELATIN IN THE FORM OF HOMELATIN CRYSTALS WITH ORGANIC ACID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |